Novo Nordisk A/S $NVO Shares Sold by Quadrant Capital Group LLC

Key Points

• Quadrant Capital Group cut its stake in Novo Nordisk by 30.0% in Q3, selling 36,116 shares and retaining 84,342 shares worth about $4.68 million at quarter end.
• Novo faces material downside risks after an FDA warning letter over semaglutide post‑marketing safety reporting and a Pomerantz investor probe, which—along with analyst downgrades—has weighed on the stock.
• Offsetting positives include a ~$506m investment to expand oral GLP‑1 production in Ireland, a distribution deal with Hims & Hers for Wegovy/Ozempic, confirmed share buybacks, a recent Q4 beat on revenue/EPS, and a $1.2751 per‑share dividend payable April 8.

Quadrant Capital Group LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 30.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,342 shares of the company's stock after selling 36,116 shares during the quarter. Quadrant Capital Group LLC's holdings in Novo Nordisk A/S were worth $4,680,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NVO. Beacon Financial Group grew its holdings in Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company's stock valued at $239,000 after purchasing an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC raised its stake in shares of Novo Nordisk A/S by 0.6% during the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company's stock worth $1,811,000 after buying an additional 200 shares during the last quarter. SeaBridge Investment Advisors LLC raised its stake in shares of Novo Nordisk A/S by 5.7% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company's stock worth $207,000 after buying an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company's stock worth $1,170,000 after buying an additional 200 shares in the last quarter. Finally, Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Capacity and production investment — Novo is expanding manufacturing in Ireland with ~ $506m to raise oral GLP‑1 output to meet global demand, which supports longer‑term volume growth and supply resilience. Novo expands manufacturing (InsiderMonkey)
• Positive Sentiment: Distribution partnership — Novo agreed to supply Wegovy/Ozempic through Hims & Hers’ telehealth platform, ending a legal dispute and opening a digital channel that could broaden U.S. access and sales. That deal helped calm one litigation front and may support volume. Novo-Hims deal (Reuters)
• Positive Sentiment: Share repurchase — Novo confirmed ongoing share buybacks (part of up to DKK15bn programme), which is supportive for shareholder returns and EPS. Share repurchase programme (GlobeNewswire)
• Neutral Sentiment: Past earnings vs. guidance — Novo beat Q4 consensus on revenue and EPS but earlier issued weak FY2026 guidance that pressured the stock; investors now weigh strong recent results against management’s cautious full‑year outlook. Q4 results & guidance (Seeking Alpha)
• Negative Sentiment: FDA warning letter — The U.S. FDA issued a warning letter after an inspection tied to Plainsboro (early 2025) citing failures in post‑marketing safety reporting for semaglutide products; the regulator flagged potential unreported adverse events including two deaths and a suicide — a material safety/regulatory risk that spooked investors. FDA warning (Reuters) Potential unreported side effects (Forbes)
• Negative Sentiment: Legal / investor risk — A law firm (Pomerantz) has launched an investigation on behalf of investors, increasing potential litigation/legal-cost overhangs. Investor investigation (GlobeNewswire)
• Negative Sentiment: Analyst downgrades and pipeline concerns — TD Cowen cut NVO to Hold and other analysts flagged the pipeline as “not poised to blunt semaglutide loss‑of‑exclusivity” and rising competitive pressure from new GLP‑1 entrants, pressuring forward expectations and valuation. Pipeline downgrade (Yahoo Finance)
• Negative Sentiment: Market reaction / sector weakness — Healthcare indices were weaker intraday as investors rotated away from GLP‑1 names amid safety/regulatory headlines and heightened competition; that broad sentiment hit NVO alongside the specific company news. Sector decline (Yahoo Finance)

Novo Nordisk A/S Trading Down 2.6%

Novo Nordisk A/S stock opened at $38.73 on Wednesday. The stock has a 50-day moving average price of $50.93 and a 200 day moving average price of $52.11. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57. The stock has a market cap of $172.92 billion, a PE ratio of 11.16 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S's dividend payout ratio is presently 23.63%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NVO. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, February 5th. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.